Newbiologix announces Weißbuch to improve the production of recombinant adeno-associated viruses for use in cell and gene therapies

Lausanne, Switzerland, March 5, 2025 (Globe Newswire) -Newbiologix, a technology innovation company pioneering work, efficient, cost-effective and scalable production of vectors for genes and cell therapy that have now published a scientific white paper in which the use of Advanthtical tools that the new Bin Adeno-Adeno-Adeno-Adeno-Adeno-Association Viruses for the analysis of the willingness of the willingness of Adieren from adeno-associated viruses (Raavs Analysis to characterize the-adeno-associated viruses that create on-call-adeno-associdated virus virus virus virus virus virus published.

RaAV is the most frequently used virus vector in gene therapy, as it effectively aimed at providing genetic material and the ability to target the target group on certain tissue. The paper examines advanced technologies that Newbiologix uses, including multi -dimensional digital PCR and third generation sequencing pipelines. These technologies act as significant quality control measures that improve the manufacturing processes for RAAV-based therapeutic agents and promote the development of more efficient cell and gene therapies.

EFRAIN Guzman, VP, Innovation & Business Development at Newbiologix said: “If we want to produce high-quality therapeutic products, everything starts with the best available cell line. That is why we generated XCELL ™ HEK293-accompanied with advanced analyzes to ensure the highest quality for transforming therapeutic solutions.”

Igor Fisch, CEO and co-founder of Newbiologix, said: “Our ambition is to become the leading company for the provision of solutions for genetic therapies based on Swiss engineering and precision. Our white paper outlines how our technological know-how, including our groundbreaking NGS integration platform Treatments should benefit in order to satisfy the increasing demand for economically viable, large scale of vectors for gene therapy.

Last year, Newbiologix launched its XCELL ™ portfolio, a number of advanced technologies that delivers deep knowledge and a comprehensive analysis of RAAV quality, which is a continuous challenge in this area. By integrating its proprietary hek293-based cell lines with advanced production tools and analytical test services, the XCELL portfolio optimizes the journey from research to commercialization and accelerates the development of more secure and effective gene therapies for patients.

Further insights and downloading the full white paper “Recombinant AAV characterization using sequencing technologies for the third generation to evaluate RaAV quality and security” can be found here.

About Newbiologix SA

New Biologix SA is a biotechnology company that is innovative for Swiss solutions and technologies for gene and cell therapy production. The company supports a special focus in this area with deep specialist knowledge in the cell line engineering. Newbiologix deals with the restrictions on gene therapy production with its complete suite of progressive cell lines for licensing and platform -based services. By making it possible to produce more reliable, safe gene therapies faster and on a scale, the company shapes the future of patient health faster and on a scale. Visit our website and follow us under LinkedIn.

Media contacts

Newbiologix

Deborah Ley, COO

[email protected]

Scius communication

Katja Stout, [email protected]+44 7789 435990

Daniel Gooch, [email protected]+44 7747 875479